linjc16/ctgov huggingface dataset:
Triage Liaison Physician - Evaluation of a Novel Approach to Address Emergency Department Overcrowding

Study Overview
=================
Brief Summary
-----------------
This randomized controlled trial will introduce a triage liaison physician (TLP) into the University of Alberta Hospital Emergency Department (ED) and assess the influence on patients who leave without being seen, ED length of stay, and other ED Overcrowding outcomes.

Detailed Description
-----------------
ED Overcrowding is a significant cause of delayed care, patient dissatisfaction, and poor outcomes in North American EDs. This intervention has not been widely studied; however, it represents an opportunity for improving patient flows in EDs.

Official Title
-----------------
Randomized Controlled Trial of a Liaison Physician at the Triage Desk to Reduce Emergency Department Overcrowding and Improve Patient Flow.

Conditions
-----------------
Acute Illness

Intervention / Treatment
-----------------
* Behavioral: Triage Liaison Physician


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Only adult patients (> 17 years of age) presenting to the University of Alberta Hospital Emergency Department (UAH ED), during the study interval will be included in the evaluation. Exclusion Criteria: Direct admits/Pediatric patients.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: 1<br>No triage liaison physician | Behavioral: Triage Liaison Physician<br>* triage liaison physician stationed with nurses at the triage desk of the Emergency Department.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Median patient length of stay |  | while in the Emergency Department | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Left without being seen |  | while in the Emergency Department | 
| ambulance turnaround times |  | while in the Emergency Department | 
| satisfaction (physicians and nurses) |  | following their Emergency Department shift | 
| TLP activity |  | while in the Emergency Department | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ED Overcrowding, Length of stay, Emergency triage, triage
SLNB After Nipple Sparing Mastectomy

Study Overview
=================
Brief Summary
-----------------
Sentinel Lymph Node Biopsy (SLNB) after nipple sparing mastectomy (NSM) is controversial. This study aims to investigate feasibility of SLNB with radioisotope method.

Detailed Description
-----------------
Volunteer patients who has underwent to NSM at least more than 6 months prior will be included to the study. Radioisotope will be injected via intradermal route to the breast underwent to NSM patients and lymphoscintigraphy images will be obtained to detect activity in axilla. If hot nodule is detected then it will be concluded that SLNB can be performed after NSM.

Official Title
-----------------
Sentinel Lymph Node Biopsy After Nipple Sparing Mastectomy: Prospective Study

Conditions
-----------------
Sentinel Lymph Node Biopsy, Mastectomy, Subcutaneous

Intervention / Treatment
-----------------
* Diagnostic Test: Senti-Scint (99mTc- pertechnetate combined with human albumin)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: NSM with/without SLNB at least 6 months prior to this study - Exclusion Criteria: previous axillary dissection and active breast cancer -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Axilla no touch<br>Volunteer patients who did not underwent to SLNB or axillary lymph node dissection during previous NSM | Diagnostic Test: Senti-Scint (99mTc- pertechnetate combined with human albumin)<br>* Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.<br>|
| Active Comparator: Axilla with previous SLNB<br>Volunteer patients who has underwent to SLNB but not axillary lymph node dissection during previous NSM | Diagnostic Test: Senti-Scint (99mTc- pertechnetate combined with human albumin)<br>* Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Enhancement in axilla | Hot nodules will be showed in axilla after injection of SENTI-SCINT | 4 hours after injection |
A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of saxagliptin administered before breakfast for 14 consecutive days in patients with type 2 diabetes mellitus.

Official Title
-----------------
A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus

Conditions
-----------------
Diabetes

Intervention / Treatment
-----------------
* Drug: saxaglipitin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who meet all of the following criteria will be included: HbA1c level ≥7.0% and < 9.0% Fasting glucose level ≥130mg/dL and <210mg/dL Patients who are capable of giving informed consent Patients who are able to take contraceptive measures to avoid pregnancy of the patient or the patient's partner for the entire study period and for 4 weeks after completion of the study Exclusion Criteria: Patients with type 1 diabetes mellitus; patients with diabetes mellitus due to other specified drugs, mechanisms, or diseases; and patients with gestational diabetes mellitus Patients with a medical history of diabetic coma Patients with heart failure Patients with a complication of active chronic hepatitis or hepatic cirrhosis Patients undergoing treatment of glomerular diseases other than diabetic nephropathy Patients with a history or complication of malignant tumor

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: saxagliptin<br>5 mg daily for 14days | Drug: saxaglipitin<br>* oral administration of 5 mg tablet before breakfast for 14 consecutive days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics | Concentrations of plasma saxagliptin and BMS-510849 | daily, up to 42days | 
| Pharmacodynamics | Plasma DPP4 actyivity Concentrations of blood glucose, C-peptide, insulin and glucagon Plasma active GLP-1 concentration | daily, up to 42 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety issues | Adverse events, skin symptom findings, blood pressure and pulse rate, body temperature, body weight, hypoglycemic symptoms, 12-lead ECG, clinical laboratory tests, and pregnancy test (in women of childbearing potential only) | daily, up to 42 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Type 2
Morbimortality in Older Patients Undergoing Urgent Abdominal Surgery

Study Overview
=================
Brief Summary
-----------------
Morbimortality in older patients undergoing abdominal surgery.

Detailed Description
-----------------
The aim of this study is to validate the modified CriSTAL tool for 30 mortality in elderly patients undergoing urgent abdominal surgery. To provide a new tool that could be used in conjunction with clinical judgment to aid in decision-making. The second objective of our study was to assess the quality of life, frailty, functional status and nutritional status in elderly patients that survive six months after an urgent abdominal surgery.

Official Title
-----------------
Analysis of Morbimortality and Functional Status in Older Patients(>65 Years Old) Undergoing Urgent Abdominal Surgery Using CRISTAL Score Modify

Conditions
-----------------
Surgery--Complications

Intervention / Treatment
-----------------
* Procedure: surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: >65 years old, accepted in emergency department Exclusion Criteria: not sign the consent

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 110 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| surgical management<br>Patient older than 65 years old, undergoing urgent abdominal surgery in our center | Procedure: surgery<br> <br> |
| not surgical management<br>Patients that presents a surgical disease, but we desestimate surgical procedure | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Barthel index, questionnaire | to measure performance in activities of daily living | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clavien- Dindo Modified | Morbimortality using Clavien-Dindo classification | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Urgent abdominal surgery. Quality of life, functional status, frailty, nutritional status
Leukemia Cell Cultures for Research of New Anti-Cancer Therapies

Study Overview
=================
Brief Summary
-----------------
The main objective of this project is not only a better understanding of the human leukemic disease but also to find new anti-leukemic or improve existing ones. This study has, the following aims: To analyze the genetic and epigenetic regulation of the retinoic acid induced cascade which leads to the expression of TRAIL in blood cells of patients with acute leukemia. This study will be complemented by the analysis of global gene expression (DNA chips) and of the DNA methylation state, and by chromatin immunoprecipitation experiences. To determine the efficiency of inhibitors of enzymes responsible for the modification of chromatin (existing and new developments within the European consortium EPITRON coordinated by Dr Gronemeyer) as inducers of differentiation and / or apoptosis of leukemic blasts. To explore Ikaros genic and functional abnormalities (genomic deletions, mutations, abnormal transcripts and proteins) in acute leukemia. The aim is to determine if these abnormalities may play a prognosis role.

Official Title
-----------------
Leukemia Cell Cultures for Research of New Anti-cancer Therapies

Conditions
-----------------
Acute Leukaemia

Intervention / Treatment
-----------------
* Procedure: Blood sampling
* Procedure: Bone marrow aspiration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with suspected de novo or secondary or relapsed acute leukemia, requiring complementary blood test and bone marrow analysis Patients older or equal than 28 days Informed consent signed Exclusion Criteria: Pregnancy Breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 28 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Procedure: Blood sampling<br> <br> Procedure: Bone marrow aspiration<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Leukaemia, Blood and marrow cells culture, Cell growth, Cell differentiation
Emergency Peripartum Hysterectomy: A Prospective Study in Iran

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the effects of peripartum hysterectomy for maternal hemorrhage.

Detailed Description
-----------------
Emergency peripartum hysterectomy is a life-saving surgical procedure which performed to control massive hemorrhage. This study was conducted to determine the factors leading to and maternal mortality and morbidity rates among the women whose underwent peripartum hysterectomy with the focus on referral or non-referral patient status.

Official Title
-----------------
Study of Peripartum Hysterectomy for Maternal Hemorrhage

Conditions
-----------------
Postpartum Hemorrhage

Intervention / Treatment
-----------------
* Procedure: hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women who have nonresponse hemorrhage after delivery Exclusion Criteria: Women who delivered before 24 weeks
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: peripartum<br>patients whom underwent peripartum hysterectomy | Procedure: hysterectomy<br>* excluding the uterus with saving ovaries<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| death rate |  | at 2 minutes after operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| urological complication |  | at 2 minutes after operation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Peripartum, hysterectomy, placenta accreta, mortality
The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery

Study Overview
=================
Brief Summary
-----------------
The role of preoperative oral immunonutrition in major vascular surgery. The mean purpose of this study was to determine the prevalence of post-operative infection complications after major vascular surgery in group of patients with preoperative oral immunonutrition. This group was compared to a control group. Secondary purpose was to evaluate the effect of preoperative oral immunonutrition on postoperative mortality (30 days), the medium length of stay in the hospital and the cost of treatment in the two groups

Official Title
-----------------
The Role of Preoperative Oral Immunonutrition in Major Vascular Surgery

Conditions
-----------------
Undernutrition

Intervention / Treatment
-----------------
* Dietary Supplement: Impact
* Dietary Supplement: Oral Impact


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Intervention planned since at least 5 days before surgery Duration of hospitalization of at least 5 days Exclusion Criteria: Pregnant or lactating woman Patient with severe renal insufficiency Patient under 18 years old Patient infected with HIV,hépatitis B or C

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Impact<br>patient receiving 3 drinks Impact a day during 5 days before surgery | Dietary Supplement: Impact<br>* Patient receiving 3 drinks Impact a day during 5 days before surgery<br>|
| Experimental: Oral Impact<br>Patient receiving 3 drinks Oral Impact a day during 5 days before surgery | Dietary Supplement: Oral Impact<br>* Patient receiving 3 drinks Oral Impact a day during 5 days before surgery<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight |  | before surgery, five days and thirty days after surgery | 
| Arisen of an infectious complication |  | during the period of 30 days following the surgery | 
| Arisen of non infectious complication |  | during the period of 30 days following the surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary and secondary permeability |  | at 5 and 30 days after surgery | 
| Pain |  | at 5 and 30 days after surgery | 
| Healing |  | at 5 and 30 days after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patients, Suffering, Undernutrition, Requiring, Vascular, Surgery
LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

Study Overview
=================
Brief Summary
-----------------
Hypertension is an increasingly important medical and public health issue. Literature suggests that there may be a role for dairy foods in the prevention and treatment of hypertension. Recently, it has been suggested that several peptides in milk proteins could have blood pressure lowering properties. LACTOPRES is a randomised, double-blind parallel trial to assess the blood pressure effect of an increased intake of dairy peptides in humans.

Official Title
-----------------
LACTOPRES:Study on the Effect of Dairy Peptides on Blood Pressure in Untreated Hypertensive Subjects.

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Behavioral: dairy peptides


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: systolic blood pressure >= 140 mmHg BMI between 18 and 32 kg/m2 apparently healthy Exclusion Criteria: antihypertensive medication medically prescribed or slimming diet lactating, pregnant irregular pulse

Ages Eligible for Study
-----------------
Minimum Age: 35 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: dairy peptides|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood pressure |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hypertension, blood pressure, dairy peptides, bioactive peptides, randomized controlled trial
Analysis of Antihypertensive Treatment Efficacy

Study Overview
=================
Brief Summary
-----------------
Analysis of antihypertensive treatment efficacy.

Official Title
-----------------
Analysis of Antihypertensive Treatment Efficacy

Conditions
-----------------
Arterial Hypertension

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: arterial hypertension intake of Atacand before study enrollment Exclusion Criteria: hypersensitivity to candesartan or any other ingredient of Atacand liver function impairment and/or cholestasis severe renal insufficiency (serum creatinine > 265 µmol/L) Pregnant and lactating women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Male or female with arterial hypertension | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analysis of antihypertensive treatment efficacy. |  | measurement BP: 3 visits for 3 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Arterial Hypertension